JP6093307B2 - ウイルス感染の治療および予防のための新規シクロスポリン誘導体 - Google Patents

ウイルス感染の治療および予防のための新規シクロスポリン誘導体 Download PDF

Info

Publication number
JP6093307B2
JP6093307B2 JP2013542244A JP2013542244A JP6093307B2 JP 6093307 B2 JP6093307 B2 JP 6093307B2 JP 2013542244 A JP2013542244 A JP 2013542244A JP 2013542244 A JP2013542244 A JP 2013542244A JP 6093307 B2 JP6093307 B2 JP 6093307B2
Authority
JP
Japan
Prior art keywords
alkyl
hydroxy
sar
optionally substituted
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013542244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014500265A5 (enExample
JP2014500265A (ja
Inventor
ス，ズァン
ロン，ゼンギュ
ファン，ゼンニァン
ヤン，スイゾウ
Original Assignee
エス アンド ティー グローバル インク．
エス アンド ティー グローバル インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エス アンド ティー グローバル インク．, エス アンド ティー グローバル インク． filed Critical エス アンド ティー グローバル インク．
Publication of JP2014500265A publication Critical patent/JP2014500265A/ja
Publication of JP2014500265A5 publication Critical patent/JP2014500265A5/ja
Application granted granted Critical
Publication of JP6093307B2 publication Critical patent/JP6093307B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2013542244A 2010-12-03 2011-12-05 ウイルス感染の治療および予防のための新規シクロスポリン誘導体 Expired - Fee Related JP6093307B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41932610P 2010-12-03 2010-12-03
US61/419,326 2010-12-03
PCT/US2011/063295 WO2012075494A1 (en) 2010-12-03 2011-12-05 Novel cyclosporin derivatives for the treatment and prevention of a viral infection

Publications (3)

Publication Number Publication Date
JP2014500265A JP2014500265A (ja) 2014-01-09
JP2014500265A5 JP2014500265A5 (enExample) 2015-02-05
JP6093307B2 true JP6093307B2 (ja) 2017-03-08

Family

ID=46172312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013542244A Expired - Fee Related JP6093307B2 (ja) 2010-12-03 2011-12-05 ウイルス感染の治療および予防のための新規シクロスポリン誘導体

Country Status (13)

Country Link
EP (1) EP2646043B1 (enExample)
JP (1) JP6093307B2 (enExample)
CN (1) CN103249424B (enExample)
AU (1) AU2011336266B2 (enExample)
BR (1) BR112013015771A2 (enExample)
CA (1) CA2819608C (enExample)
DK (1) DK2646043T3 (enExample)
ES (1) ES2625502T3 (enExample)
MX (1) MX350746B (enExample)
PT (1) PT2646043T (enExample)
RU (1) RU2601742C2 (enExample)
WO (1) WO2012075494A1 (enExample)
ZA (1) ZA201303610B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103153329A (zh) 2010-07-16 2013-06-12 美国科技环球有限公司 新颖的环孢霉素a衍生物在病毒感染的治疗和预防中的应用
CN103153330B (zh) 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用
CA2814192A1 (en) 2010-10-12 2012-04-19 Allergan, Inc. Cyclosporin analogs
JP5805773B2 (ja) 2010-10-12 2015-11-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンアナログ
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof
US9266927B2 (en) 2012-06-01 2016-02-23 Allergan, Inc. Cyclosporin A analogs
WO2014049540A2 (en) * 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
CN105960246A (zh) * 2013-03-15 2016-09-21 美国科技环球有限公司 新型环孢菌素衍生物及其用途
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
CN109476705B (zh) * 2016-05-17 2024-02-27 美国科技环球有限公司 新型环孢菌素衍生物及其用途
EP3914655B1 (en) 2019-01-24 2025-04-23 Agfa Nv Radiation curable inkjet inks for interior decoration
EP3686252A1 (en) 2019-01-24 2020-07-29 Agfa-Gevaert Nv Radiation curable inkjet ink for manufacturing printed circuit boards
CA3128410A1 (en) * 2019-10-11 2021-04-15 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ws-635 uses thereof in medicine
WO2021209003A1 (en) 2020-04-15 2021-10-21 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries
CN112154151B (zh) * 2020-06-04 2025-04-29 中美华世通生物医药科技(武汉)股份有限公司 治疗或预防冠状病毒科感染

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0194972B1 (en) * 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
HUP9900405A3 (en) * 1995-07-17 2001-04-28 Scynexis Inc Durham Cyclosporin derivatives with anti-hiv effect
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CN101068829B (zh) * 2004-10-01 2012-05-30 西尼克斯公司 用于治疗和预防丙型肝炎病毒感染的3-醚和3-硫醚取代的环孢菌素衍生物
PL1802650T3 (pl) * 2004-10-01 2012-04-30 Scynexis Inc 3-Etero i 3-tioetero podstawione pochodne cyklosporyny do leczenia i zapobiegania zakażeniu wirusem zapalenia wątroby typu C
MX2011007195A (es) * 2009-01-07 2013-07-12 Scynexis Inc Derivado de ciclosporina para el uso en el tratamiento de infección de virus de hepatitis c (vhc) y virus de inmunodeficiencia humana (vih).
CA2751210C (en) * 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis c infection
CN103153330B (zh) * 2010-08-12 2017-08-18 美国科技环球有限公司 新的环孢霉素衍生物在病毒感染的治疗和预防中的应用

Also Published As

Publication number Publication date
DK2646043T3 (da) 2017-05-22
RU2013130256A (ru) 2015-01-10
MX350746B (es) 2017-09-14
CA2819608A1 (en) 2012-06-07
CA2819608C (en) 2020-03-31
CN103249424B (zh) 2016-08-10
RU2601742C2 (ru) 2016-11-10
EP2646043A4 (en) 2014-05-28
AU2011336266B2 (en) 2017-04-06
EP2646043B1 (en) 2017-02-15
JP2014500265A (ja) 2014-01-09
BR112013015771A2 (pt) 2018-11-06
ZA201303610B (en) 2014-07-30
AU2011336266A1 (en) 2013-06-27
ES2625502T3 (es) 2017-07-19
EP2646043A1 (en) 2013-10-09
PT2646043T (pt) 2017-05-09
MX2013006254A (es) 2013-10-30
CN103249424A (zh) 2013-08-14
WO2012075494A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
JP6093307B2 (ja) ウイルス感染の治療および予防のための新規シクロスポリン誘導体
JP7637421B2 (ja) 新規シクロスポリン誘導体及びその使用
US9573978B2 (en) Cyclosporin derivatives for the treatment and prevention of a viral infection
US9217015B2 (en) Cyclosporin derivatives for the treatment and prevention of a viral infection
US10647747B2 (en) Cyclosporin derivatives and uses thereof
EP2968445A2 (en) Novel cyclosporin derivatives and uses thereof
WO2013028615A2 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
HK1188134A (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
HK1188134B (en) Novel cyclosporin derivatives for the treatment and prevention of a viral infection
HK40005642A (en) Novel cyclosporin derivatives and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160229

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170210

R150 Certificate of patent or registration of utility model

Ref document number: 6093307

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees